Preparation and physicochemical characterization of atovaquone- containing liposomes

Drug Development Research

Volumn 47, Issue 4, 1999, Pages 155-161

  Cauchetier, E ^a,e   Fessi, H ^b   Boulard, Y ^c   Deniau, M ^c   Astier, A ^a,d   Paul, M ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

^c MUSÉUM NATIONAL D'HISTOIRE NATURELLE   (France)

^d UNIVERSITÉ DE LORRAINE   (France)

^e NONE   (France)

Author keywords

Adsorption; Atovaquone; Liposomes; Physicochemical properties

Indexed keywords

ATOVAQUONE; LIPOSOME;

ALKALINITY; ARTICLE; CONCENTRATION (PARAMETERS); DRUG ADSORPTION; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; DRUG SYNTHESIS; ENCAPSULATION; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRECIPITATION; STATISTICAL ANALYSIS;

EID: 0032833687     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199908)47:4<155::AID-DDR1>3.0.CO;2-4     Document Type: Article

References (37)

1. Alving CR. 1983. Delivery of liposome-encapsulated drugs to macrophages. Pharmac Ther 22:407-424.
2. Alving CR. 1986. Liposomes as drug carriers in leishmaniasis and malaria. Parasitol Today 2:101-106.
3. Alving CR, Steck EA, Chapman WL, Waits VB, Hendricks CD, Swartz GM, Hanson WL. 1978. Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs. Proc Natl Acad Sci USA 75:2959-2963.
4. Antoine JCI. 1995. Biologie des interactions macrophages; leishmania. Pathol Biol 43:215-223.
5. Badaro R, Nascimento C, Carvalho JS, Badaro F, Russo D, Ho JL, Reed SG, Johnson WD, Jones TC. 1994. rhGM-CSF reverses neutropenia and reduces secondary infections in visceral leishmaniasis. J Infect Dis 170:413-418.
6. Bakker-Woudenberg IAJM, Storm G, Woodle MC. 1994. Liposomes in the treatment of infections. J Drug Target 2:363-371.
7. Bartlett GRJ. 1959. Phosphorous assay in column chromatography. J Biol Chem 234:466-468.
8. Bryceson ADM. 1987. Therapy in man. In: Peters W, Killick-Kendrick R, editors. Leishmaniasis in biology and medicine. London: Academic Press, p 847-907.
9. Burroughs Wellcome. 1992. Mepron package insert. Research Triangle Park, NC.
10. Cabie A, Matheron S, Lepretre A, Bouchaud O, Deluol AM, Coulaud JP. 1992. Leishmaniose viscérale au cours de l'infection par le VIH, une infection opportuniste à part entière. La Presse Médicale 21:1658-1662.
11. Couvreur P, Kante B, Roland M, Guiot P, Bauduin P, Speiser P. 1979. Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties. J Pharm Pharmacol 31:331-332.
12. Croft S, Hogg J, Gutteridge W, Hudson A, Randall A. 1992. The activity of hydroxynaphtoquinones against Leishmania donovani. J Antimicrob Chemother 30:827-832.
13. Czuryolo EA, Zborowski J, Dabrowska R. 1993. Interaction of caldesmon with phospholipids. Biochem J 291:403-408.
14. Davidson RN, Croft SL, Scott A, Maini M, Moody AH, Bryceson ADM. 1991. Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet 337:1061-1062.
15. Davidson RN, Di Martino L, Gradoni L, Giacchino R, Russo R, Gaeta GB, Pempinello R, Scott S, Raimondi F, Cascio A, Prestileo T, Caldeira L, Wilkinson RJ, Bryceson ADM. 1994. Liposomal amphotericin B (Ambisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med 87:75-81.
16. de Chasteigner S, Fessi H, Devissaguet JP, Puisieux F. 1996. Comparative study of the association of itraconazole with colloidal drug carriers. Drug Dev Res 38:125-133.
17. Dedet JP, Lambert M, Pratlong F. 1995. Leishmanioses et infection par le virus de l'immunodéficience humaine. La Presse Médicale 24:1036-1040.
18. du Plessis J, Tiedt LR, Van Wyk CJ, Ackermann C. 1986. A new transmission electron microscope method for the determination of particule size in parenteral fat emulsion. Int J Pharm 34:173-174.
19. du Plessis J, Tiedt LR, Kotze AF, Van Wyk CJ, Ackermann C. 1988. A transmission electron microscope method for determination of droplet size in parenteral fat emulsions using negative staining. Int J Pharm 46:177-178.
20. Durand R, Paul M, Rivollet D, Houin R, Astier A, Deniau M. 1997. Activity of pentamidine loaded poly (D,L-Lactide) nanoparticles against Leishmania infantum in a mouse model. Int J Parasitol 27:1361-1367.
21. Gondal JA, Swartz RP, Rahman A. 1989. Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob Agents Chemother 33:1544-1548.
22. Harashima H, Sakata K, Kiwada H. 1993. Distinction between the depletion of opsonins and the saturation of uptake in the dose-dependent hepatic uptake of liposomes. Pharm Res 10:606-610.
23. Hwang KJ. 1983. Liposome pharmacokineties. In: Ostro MJ, editor. Liposomes: from biophysics to therapeutics. New York: Marcel Dekker. p 109-156.
24. Illum L, Khan MA, Mak E, Davis SS. 1986. Evaluation of carrier capacity and release characteristics for poly(butyl 2-cyanoacrylate) nanoparticles. Int J. Pharm 30:17-28.
25. Jernigan JA, Pearson RD, Rogers MD, Petri WA. 1993. In vitro activity of atovaquone against Leishmania chagasi promastigotes. In: Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC. Abstr. 752, p 257.
26. Kirby C, Clarke J, Gregoriadis G. 1980. Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem J 186:591-598.
27. Olliaro PL, Bryceson ADM. 1993. Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol Today 9:323-328.
28. Patel HM. 1992. Serum opsonins and liposomes: their interaction and opsonophagocytosis. Crit Rev Ther Drug Carr Syst 9:39-90.
29. Paul M, Laatiris A, Fessi H, Dufeu B, Durand R, Deniau M, Astier A. 1998. Pentamidine loaded poly (D,lactide) nanoparticles: adsorption and drug release. Drug Dev Res 43:98-104.
30. Puisieux F. 1985. Les liposomes. In: Buri P, Puisieux F, Doelker E, Benoit JP, editors. Formes pharmaceutiques nouvelles: aspects technologique, biopharmaceutique et médical. Paris: Tec and Doc. p 467-560.
31. Rodrigues JM Jr, Croft SL, Fessi H, Bories C, Devissaguet JPh. 1994. The activity and ultrastructural localization of primaquine-loaded poly (D,L-lactide) nanoparticles in Leishmania donovani infected mice. Trop Med Parasitol 45:223-228.
32. Senior JH. 1987. Fate and behaviour of liposomes in vivo: a review of controlling factors. CRC Crit Rev Ther Drug Carr Syst 3:123-193.
33. Stainmess S, Fessi H, Devissaguet JP, Puisieux F 1989. Procédé de preparation de systèmes colloïdaux dispersibles de lipides amphiphiles sous forme de liposomes submicroniques. European patent no. 894018571.
34. Tocanne JF, Teissie J. 1990. Ionization of phospholipids and phospholipid-supported interfacial lateral diffusion of proton in membrane model systems. Biochim Biophys Acta 1031:111-142.
35. Vemuri S, Rhodes CT. 1995. Preparation and characterization of liposomes as therapeutic delivery systems: a review. Pharm Acta Helv 70:95-111.
36. Wissner A. 1990. HMO version 1.1: a Huckel molecular orbital program for the Macintosh. Tetrahedron Comput Methodol 3:63-71.
37. Zografi G. 1995. Interfacial phenomena. In: Gennaro AR, editor. Remington: the science and practice of pharmacy, 19th ed. Easton, PA: Mac Publishing, p 249.